A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms SELECT Axis 1
  • Sponsors AbbVie
  • Most Recent Events

    • 08 Nov 2017 Planned number of patients changed from 228 to 170.
    • 08 Nov 2017 Planned End Date changed from 27 Sep 2020 to 3 Oct 2020.
    • 08 Nov 2017 Planned primary completion date changed from 5 Nov 2018 to 7 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top